{"title":"Rethinking TREM2 as a target for Alzheimer’s disease after the INVOKE-2 trial failure","authors":"Marco Colonna, David M. Holtzman","doi":"10.1038/s41591-025-03816-2","DOIUrl":null,"url":null,"abstract":"<p>When Alector announced in late 2024 that its phase 2 trial of AL002, a monoclonal antibody that targets TREM2, had failed to slow cognitive decline in Alzheimer’s disease (AD), it reignited debate over the viability of microglial targets in AD. Years of compelling genetic and preclinical research had positioned the microglial receptor TREM2 as a central player in AD pathology. Now, with the first major clinical test of a TREM2-targeting therapy falling short, the obvious question is: is TREM2 still worth pursuing?</p><p>The answer is not a simple yes or no. Instead, it depends on rethinking how this microglial receptor and its adapter, DAP12, are engaged, and recognizing that the INVOKE-2 trial may have tested the idea of TREM2 as a drug target, but not the full potential of what effective activation of TREM2 could look like in the clinic. Also, new technologies and alternative strategies suggest that the story is far from over.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"19 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03816-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
When Alector announced in late 2024 that its phase 2 trial of AL002, a monoclonal antibody that targets TREM2, had failed to slow cognitive decline in Alzheimer’s disease (AD), it reignited debate over the viability of microglial targets in AD. Years of compelling genetic and preclinical research had positioned the microglial receptor TREM2 as a central player in AD pathology. Now, with the first major clinical test of a TREM2-targeting therapy falling short, the obvious question is: is TREM2 still worth pursuing?
The answer is not a simple yes or no. Instead, it depends on rethinking how this microglial receptor and its adapter, DAP12, are engaged, and recognizing that the INVOKE-2 trial may have tested the idea of TREM2 as a drug target, but not the full potential of what effective activation of TREM2 could look like in the clinic. Also, new technologies and alternative strategies suggest that the story is far from over.
期刊介绍：
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
